Protein Discovery In The Age Of AI
Twist Bioscience’s high-throughput DNA synthesis platform is enabling AI researchers to compress protein discovery timelines and expand therapeutic possibilities.| Asian Scientist Magazine
AbbVie has been staging a generational handoff for years: as Humira’s U.S. exclusivity fell and biosimilars swarmed, the company groomed Rinvoq and Skyrizi as the next standard-bearers. Investors already know the script: AbbVie has guided the duo to more than $31 billion in combined sales by 2027, and Humira’s 2022 global peak north of $21… The post AbbVie’s RINVOQ showed superiority over HUMIRA in rheumatoid arthritis study appeared first on Drug Discovery and Development.| Drug Discovery and Development
Novo Nordisk has agreed to acquire Akero Therapeutics, a clinical-stage company that develops treatments for metabolic diseases, the company announced last week. Akero’s EFX pipeline Akero Therapeutics’ treatment for metabolic-dysfunction-associated steatohepatitis (MASH) “is closely linked with Novo Nordisk’s expertise in diabetes and obesity,” the press release stated. More than 40% of patients with MASH, formerly… The post Novo Nordisk to acquire Akero Therapeutics for $5.2 b...| Drug Discovery and Development
Twist Bioscience’s high-throughput DNA synthesis platform is enabling AI researchers to compress protein discovery timelines and expand therapeutic possibilities.| Asian Scientist Magazine
Bispecific antibodies are a rapidly advancing class of therapeutics, offering a new level of precision in treating diseases like cancer.| Drug Discovery and Development
Nektar Therapeutics stock skyrocketed 287% after rezpegaldesleukin hit all endpoints in atopic dermatitis trials, but ongoing litigation with Lilly could complicate matters.| Drug Discovery and Development
In April 2023, I received a letter from the Ontario government with information about the new biosimilar switching policy. I had until the end of the year to switch from the biologic medication I take to treat my rheumatoid arthritis (RA) to a biosimilar. I did my best to be hopeful and believe it would…| The Seated View
In March 2023, I received a letter from the Ontario government. It informed me that a biosimilar switching policy was now in place. People like me who receive funding from the government to pay for Biologics for rheumatoid arthritis (RA), Crohn’s disease, and other forms of autoimmune disease were given until the end of 2023…| The Seated View
The phase 4 EVEREST study showed that Dupixent demonstrated superiority over Xolair in adults with chronic rhinosinusitis.| Drug Discovery and Development
The FDA has approved ENFLONSIA for the prevention of RSV lower respiratory tract disease in infants and newborns.| Drug Discovery and Development
Just over three-quarters of patients receiving Sanofi and Regeneron’s Dupixent achieved at least a 75% improvement in disease severity.| Drug Discovery and Development
Learning that a biologic medicine hasn’t worked for you is hard. Being told that you have “failed” that medicine is worse. Let’s change that narrative. You didn’t fail. The medicine failed you.| CreakyJoints Australia
Were you affected by the abatacept (Orencia®) shortage this year? If so, we have great news. The supply situation in Australia has improved and you may be able to return to your previous treatment regime.| CreakyJoints Australia
